Evidence map›Paper›PMID 40486915›Full record

ReviewJournal of neuroendovascular therapy2025

Telemedicine 3.0: The Real Anywhere and Anytime.

Hiroyuki Takao, Kohei Takeshita, Kenichiro Sakai, Teppei Komatsu, Teppei Sakano, Yu Chih Yeh, Demetrius K Lopes, Raul G Nogueira, Sheila Martins, Shigeru Kawada and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of neuroendovascular therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hiroyuki TakaoDepartment of Innovation for Medical Information Technology, The Jikei University School of Medicine, Tokyo, Japan.
Kohei TakeshitaDepartment of Innovation for Medical Information Technology, The Jikei University School of Medicine, Tokyo, Japan.
Kenichiro SakaiDepartment of Neurology, The Jikei University School of Medicine, Tokyo, Japan.
Teppei KomatsuDepartment of Neurology, The Jikei University School of Medicine, Tokyo, Japan.
Teppei SakanoDepartment of Innovation for Medical Information Technology, The Jikei University School of Medicine, Tokyo, Japan.
Yu Chih YehDepartment of Innovation for Medical Information Technology, The Jikei University School of Medicine, Tokyo, Japan.
Demetrius K LopesCerebrovascular and Comprehensive Stroke Center, Advocate Illinois Masonic Medical Center, Chicago, IL, USA.
Raul G NogueiraDivision of Cerebrovascular Medicine, UPMC Stroke Institute, Pittsburgh, PA, USA.
Sheila MartinsDepartment of Neurology and Neurosurgery, Hospital Moinho dos Ventos, Porto Alegre, RS, Brazil.
Shigeru KawadaDepartment of Innovation for Medical Information Technology, The Jikei University School of Medicine, Tokyo, Japan.
Issei KanDepartment of Neurosurgery, The Jikei University School of Medicine, Tokyo, Japan.
Toshihiro IshibashiDepartment of Neurosurgery, The Jikei University School of Medicine, Tokyo, Japan.
Yasuyuki IguchiDepartment of Neurology, The Jikei University School of Medicine, Tokyo, Japan.
Yuichi MurayamaDepartment of Neurosurgery, The Jikei University School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical applications of telemedicine using digital technology are in demand in Japan and continue to expand. However, with some exceptions, it would be difficult to say that the current situation is adequate in terms of encouraging research and development, formulating guidelines that need to be established before telemedicine can spread, and providing support programs for these activities. The "Telestroke" telemedicine system for the treatment of stroke has been adopted in other countries due to the early establishment of a medical device program compatible with guidelines and the steady accumulation of evidence, creating a situation that leads the world. With optimization of the support program from the perspective of strategically produced evidence by governments and related organizations, and by taking these results as model cases for other regions, telemedicine in Japan is thought to progress to a new stage.

Indexed as

digital technologyguidelineshealthcare policyresearch and developmenttelemedicine

Identifiers

PMID40486915
PMCPMC12141459

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.